vs

Side-by-side financial comparison of Astrana Health, Inc. (ASTH) and CIMPRESS plc (CMPR). Click either name above to swap in a different company.

CIMPRESS plc is the larger business by last-quarter revenue ($1.0B vs $950.5M, roughly 1.1× Astrana Health, Inc.). CIMPRESS plc runs the higher net margin — 4.7% vs 0.7%, a 4.0% gap on every dollar of revenue. On growth, Astrana Health, Inc. posted the faster year-over-year revenue change (42.9% vs 11.0%). CIMPRESS plc produced more free cash flow last quarter ($139.5M vs $-6.0M).

Astrana Health, Inc. is a U.S.-based value-based healthcare services provider that primarily serves Medicare-eligible senior populations across the United States. It offers in-home primary care, chronic disease management, and care coordination services, aiming to improve patient health outcomes and reduce unnecessary medical costs.

Cimpress plc is an American Irish-domiciled multinational technology company that invests in and operates a wide variety of businesses that use mass customization to configure and produce small quantities of individually customized goods. Those products are sold to small businesses, graphic designers and consumers through a number of customer-facing brands that Cimpress operates.

ASTH vs CMPR — Head-to-Head

Bigger by revenue
CMPR
CMPR
1.1× larger
CMPR
$1.0B
$950.5M
ASTH
Growing faster (revenue YoY)
ASTH
ASTH
+31.9% gap
ASTH
42.9%
11.0%
CMPR
Higher net margin
CMPR
CMPR
4.0% more per $
CMPR
4.7%
0.7%
ASTH
More free cash flow
CMPR
CMPR
$145.4M more FCF
CMPR
$139.5M
$-6.0M
ASTH

Income Statement — Q4 FY2025 vs Q2 FY2026

Metric
ASTH
ASTH
CMPR
CMPR
Revenue
$950.5M
$1.0B
Net Profit
$6.6M
$49.3M
Gross Margin
46.8%
Operating Margin
1.9%
8.5%
Net Margin
0.7%
4.7%
Revenue YoY
42.9%
11.0%
Net Profit YoY
184.4%
-19.2%
EPS (diluted)
$0.12
$1.95

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTH
ASTH
CMPR
CMPR
Q4 25
$950.5M
$1.0B
Q3 25
$956.0M
$863.3M
Q2 25
$654.8M
Q1 25
$620.4M
Q4 24
$665.2M
Q3 24
$478.7M
Q2 24
$486.3M
Q1 24
$404.4M
Net Profit
ASTH
ASTH
CMPR
CMPR
Q4 25
$6.6M
$49.3M
Q3 25
$373.0K
$7.6M
Q2 25
$9.4M
Q1 25
$6.7M
Q4 24
$-7.8M
Q3 24
$16.1M
Q2 24
$19.2M
Q1 24
$14.8M
Gross Margin
ASTH
ASTH
CMPR
CMPR
Q4 25
46.8%
Q3 25
46.7%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
ASTH
ASTH
CMPR
CMPR
Q4 25
1.9%
8.5%
Q3 25
2.0%
5.7%
Q2 25
3.1%
Q1 25
3.3%
Q4 24
0.1%
Q3 24
5.9%
Q2 24
6.2%
Q1 24
7.5%
Net Margin
ASTH
ASTH
CMPR
CMPR
Q4 25
0.7%
4.7%
Q3 25
0.0%
0.9%
Q2 25
1.4%
Q1 25
1.1%
Q4 24
-1.2%
Q3 24
3.4%
Q2 24
3.9%
Q1 24
3.7%
EPS (diluted)
ASTH
ASTH
CMPR
CMPR
Q4 25
$0.12
$1.95
Q3 25
$0.01
$0.30
Q2 25
$0.19
Q1 25
$0.14
Q4 24
$-0.14
Q3 24
$0.33
Q2 24
$0.40
Q1 24
$0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTH
ASTH
CMPR
CMPR
Cash + ST InvestmentsLiquidity on hand
$429.5M
$258.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$779.3M
$-530.7M
Total Assets
$2.2B
$2.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTH
ASTH
CMPR
CMPR
Q4 25
$429.5M
$258.0M
Q3 25
$463.4M
$200.5M
Q2 25
$342.1M
Q1 25
$260.9M
Q4 24
$290.8M
Q3 24
$350.3M
Q2 24
$327.7M
Q1 24
$337.3M
Stockholders' Equity
ASTH
ASTH
CMPR
CMPR
Q4 25
$779.3M
$-530.7M
Q3 25
$775.5M
$-571.3M
Q2 25
$765.5M
Q1 25
$745.4M
Q4 24
$712.7M
Q3 24
$704.6M
Q2 24
$678.9M
Q1 24
$653.5M
Total Assets
ASTH
ASTH
CMPR
CMPR
Q4 25
$2.2B
$2.1B
Q3 25
$2.2B
$2.0B
Q2 25
$1.4B
Q1 25
$1.3B
Q4 24
$1.4B
Q3 24
$1.3B
Q2 24
$1.3B
Q1 24
$1.2B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTH
ASTH
CMPR
CMPR
Operating Cash FlowLast quarter
$-2.9M
$164.7M
Free Cash FlowOCF − Capex
$-6.0M
$139.5M
FCF MarginFCF / Revenue
-0.6%
13.4%
Capex IntensityCapex / Revenue
0.3%
2.4%
Cash ConversionOCF / Net Profit
-0.44×
3.34×
TTM Free Cash FlowTrailing 4 quarters
$104.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTH
ASTH
CMPR
CMPR
Q4 25
$-2.9M
$164.7M
Q3 25
$10.0M
$25.1M
Q2 25
$90.9M
Q1 25
$16.6M
Q4 24
$-10.9M
Q3 24
$34.0M
Q2 24
$23.2M
Q1 24
$6.0M
Free Cash Flow
ASTH
ASTH
CMPR
CMPR
Q4 25
$-6.0M
$139.5M
Q3 25
$7.4M
$-1.3M
Q2 25
$89.5M
Q1 25
$13.6M
Q4 24
$-13.5M
Q3 24
$31.7M
Q2 24
$20.4M
Q1 24
$5.6M
FCF Margin
ASTH
ASTH
CMPR
CMPR
Q4 25
-0.6%
13.4%
Q3 25
0.8%
-0.1%
Q2 25
13.7%
Q1 25
2.2%
Q4 24
-2.0%
Q3 24
6.6%
Q2 24
4.2%
Q1 24
1.4%
Capex Intensity
ASTH
ASTH
CMPR
CMPR
Q4 25
0.3%
2.4%
Q3 25
0.3%
3.1%
Q2 25
0.2%
Q1 25
0.5%
Q4 24
0.4%
Q3 24
0.5%
Q2 24
0.6%
Q1 24
0.1%
Cash Conversion
ASTH
ASTH
CMPR
CMPR
Q4 25
-0.44×
3.34×
Q3 25
26.69×
3.28×
Q2 25
9.65×
Q1 25
2.48×
Q4 24
Q3 24
2.11×
Q2 24
1.21×
Q1 24
0.40×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTH
ASTH

Medicare$542.4M57%
Commercial$99.1M10%
Care Delivery$92.1M10%
Care Enablement$78.9M8%
Other Third Parties$58.0M6%
Health Care Patient Service$39.8M4%
Health Care Other$25.5M3%
Other$12.1M1%
Management Service$10.3M1%

CMPR
CMPR

Vista$532.8M51%
Print Brothers$219.9M21%
National Pen$150.9M14%
The Print Group$115.2M11%
All Other Businesses$67.2M6%

Related Comparisons